Evidence map›Paper›PMID 33300059›Full record

Trial reportMolecular medicine reports2021

Long non‑coding RNA ANRIL is a potential indicator of disease progression and poor prognosis in acute myeloid leukemia.

Zhenqing Tan, Kaibo Zhu, Yafei Yin, Zimian Luo

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zhenqing TanDepartment of Hematology, Central Hospital of Xiangtan, Xiangtan, Hunan 411100, P.R. China.
Kaibo ZhuDepartment of Hematology, Central Hospital of Xiangtan, Xiangtan, Hunan 411100, P.R. China.
Yafei YinDepartment of Hematology, Central Hospital of Xiangtan, Xiangtan, Hunan 411100, P.R. China.
Zimian LuoDepartment of Hematology, Central Hospital of Xiangtan, Xiangtan, Hunan 411100, P.R. China.
Xiangyang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study explored the association of long non‑coding RNA (lncRNA) antisense non‑coding RNA in the INK4 locus (ANRIL) with the development of acute myeloid leukemia (AML) clinical features and prognosis of patients with AML. Bone marrow mononuclear cells (BMMCs) were obtained from 178 patients with

Indexed as

Gene Expression Regulation, LeukemicLeukemia, Myeloid, AcuteAdultAgedBone Marrow CellsDisease-Free SurvivalFemaleHumansLeukocytes, MononuclearMaleMiddle AgedRNA, Long NoncodingRNA, NeoplasmSurvival RateCDKN2B antisense RNA, humanRNA, Long NoncodingRNA, Neoplasmacute myeloid leukemiadisease risklong non‑coding RNA ANRILprognosisrisk stratification

Identifiers

PMID33300059
PMCPMC7723160
OpenAlexW3107954763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.